Bristol-Myers Squibb Company (BMY)
| Market Cap | 104.40B |
| Revenue (ttm) | 44.94B |
| Net Income (ttm) | 8.29B |
| Shares Out | 2.03B |
| EPS (ttm) | 3.94 |
| PE Ratio | 13.02 |
| Forward PE | 6.68 |
| Dividend | $2.40 (4.68%) |
| Ex-Dividend Date | Jan 4, 2024 |
| Volume | 9,027,777 |
| Open | 51.13 |
| Previous Close | 51.22 |
| Day's Range | 50.99 - 51.49 |
| 52-Week Range | 48.25 - 75.18 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 63.94 (+24.62%) |
| Earnings Date | Feb 2, 2024 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and p... [Read more]
Financial Performance
In 2022, BMY's revenue was $46.16 billion, a decrease of -0.49% compared to the previous year's $46.39 billion. Earnings were $6.33 billion, a decrease of -9.54%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for BMY stock is "Buy." The 12-month stock price forecast is $63.94, which is an increase of 24.62% from the latest price.
News
RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RayzeBio, Inc. (...
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Karuna Therapeut...
Bristol Myers Squibb's big buys: $18.1 billion in 2 biotech deals
On December 22, the pharma giant said it was acquiring Karuna Therapeutics Inc. NASDAQ: KRTX for $330 per share in cash, for a total equity value of $14 billion.
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceutic...
After a bruising 2023, Bristol-Myers Squibb (BMY) forges a risky M&A strategy
Bristol-Myers Squibb (NYSE: BMY), the giant pharmaceutical company, had a difficult year as its stock tanked. Its shares crashed by over 28% in 2023, becoming one of the top laggards of the S&P 500 in...
Bristol to Buy Drug Developer RayzeBio for $4.1 Billion
Bristol Myers Squibb Co. agreed to buy radiological drug developer RayzeBio Inc. for about $4.1 billion, the latest deal in a buying spree to bolster its pipeline. Bloomberg's Madison Mueller reports.
The state of pharmaceuticals: Bristol-Myers Squibb's plan to buy RayzeBio
Jared Hopkins, Wall Street Journal, joins 'The Exchange' to discuss Bristol-Myers Squibb's plan to buy RayzeBio.
Bristol Myers Squibb Buys RayzeBio, Its Second Multibillion-Dollar Deal in Days
RayzeBio Inc. (RYZB) shares skyrocketed Tuesday after Bristol Myers Squibb Co. (BMY) said it was buying the radiopharmaceutical therapy company for $4.1 billion to expand its cancer treatment options....
Midday Movers: Intel's Israel Deal, Bristol-Myers Squibb Buys RayzeBio
Christmas may be over, but the so-called “Santa Claus rally” continued for U.S. equities at midday in the shortened final trading week of 2023. The Dow, S&P 500, and Nasdaq were all in positive territ...
Bristol Myers to buy RayzeBio for about $4.1B
The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.
Bristol Myers strikes $4.1 bln RayzeBio deal for targeted cancer therapies
Dec 26 (Reuters) - Bristol Myers Squibb (BMY.N) said on Tuesday it would buy RayzeBio (RYZB.O) for about $4.1 billion to bolster its cancer drug business, marking the second multi-billion dollar deal ...
Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion
RayzeBio is being bought for $62.50 a share in cash.
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb's Leading Oncology Franc...
Bristol Myers to buy RayzeBio for more than 100% premium, in a deal valued at $4.1 billion
Bristol Myers Squibb Co. BMY announced Tuesday an agreement to buy radiopharmaceutical therapeutics company RayzeBio Inc. RYZB in a deal valued at $4.1 billion. Under terms of the deal, Bristol Myers ...
Bristol-Myers buying Karuna signals a biotech boom ahead: Jefferies
Karuna Therapeutics Inc (NASDAQ: KRTX) ended nearly 50% up on Friday after Bristol-Myers Squibb Co (NYSE: BMY) said it will buy the biopharmaceutical firm for $14 billion.
Biotech boom ahead in 2024, top Jefferies analyst predicts on heels of Bristol Meyers-Karuna deal
Michael Yee, Jefferies Senior Biotech Analyst, joins 'Fast Money' to talk a possible boom ahead for the biotech sector.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Karuna Therapeutics, Inc.
NEW YORK , Dec. 22, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Karuna Therapeutics, Inc. (NASDAQ: KRTX) and its board of directors concerning the prop...
Bristol Myers Squibb to buy Karuna Therapeutics for $14 billion in cash
Stephanie Link and Jim Lebenthal join 'Halftime Report' to discuss Bristol Myers Squibb's latest announcement to buy Karuna Therapeutics for $14 billion.
Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook
U.S. equities headed into the long holiday weekend with gains at midday, amid a broad-based rally fueled by enthusiasm over the possibility of several Fed interest rate cuts next year. The Dow, S&P 50...
Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna Deal
Karuna Therapeutics (KRTX) shares skyrocketed over 46% after Bristol Myers Squibb (BMY) said it would buy the biopharmaceutical firm for $14 billion to expand its neuroscience portfolio.
Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 bln
Dec 22 (Reuters) - Bristol Myers Squibb (BMY.N) on Friday agreed to buy Karuna Therapeutics (KRTX.O) for $14 billion, gaining a promising new type of antipsychotic medicine to help power growth as pat...
Bristol Myers acquiring Karuna Therapeutics in $14B deal
Bristol Myers Squibb (BMY) is buying biopharmaceutical company Karuna Therapeutics (KRTX) for $330.00 per share, with the deal valued at $14 billion. Karuna has an experimental schizophrenia drug that...
Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal
Bristol Myers Squibb said it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash.